Contact Support +1-(281)-619-8646
Free Addition on COVID-19 Impact Analysis                        Upto 15% Discounts for all Research Reports
Report Store

Irritable Bowel Syndrome Treatment Market

Irritable Bowel Syndrome Treatment Market
  • MMC004285
  • Category: Healthcare & Life Sciences
  • Dec.2024
  • Publisher id : Meridian Market Consultants
  • No. of pages : 265
  • Rating :
  • Format : PDF,PPT

    
    
    


  • Report Description
  • Table Of Content
  • Request Sample

Irritable Bowel Syndrome Treatment Market Overview

The report is titled ‘Irritable Bowel Syndrome Treatment Market: Opportunity Analysis and Future Assessment 2020-2028’. An overview of conceptual frameworks, analytical approaches of the irritable bowel syndrome treatment market is the main objective of the report, which further consists of the market opportunity and insights of the data involved in the making of the respective market. The irritable bowel syndrome treatment market is expected to grow at a significant rate in the near future.

The irritable bowel syndrome treatment market size was valued at US$ 1.8 Bn in 2020 and is expected to expand at a compound annual growth rate (CAGR) of 8.5% from 2020 to 2028.

Irritable Bowel Syndrome Treatment Market Definition

Irritable bowel syndrome can be perceived as a gastrointestinal tract disorder marked by abdominal trouble and changed bowel customs. It hinders the natural motion of intestinal muscle linings to drive food along the digestive tract. Contingent on the signs and symptoms, the irritable bowel syndrome is segregated as mild and intense irritable bowel syndrome. The symptoms for the irritable bowel syndrome include abdominal pain, cramping, gas and bloating, constipation, mucus in the stool, and diarrhea.

Irritable Bowel Syndrome Treatment Market Dynamics

The rapid surge in the geriatric population across the world and resultantly, rapid surge in the prevalence of gastrointestinal disorders and diseases such as variation of bowel habit and abdominal trouble is majorly driving the irritable bowel syndrome treatment market.

In addition to that, the high soar in the stress level among the population, in the modern day and age, as well as poor diet and sickly lifestyle due to busy schedules and desk-bound jobs are another major factors that is estimated to boost the growth of the global irritable bowel syndrome treatment market in the years to come.

Although, people have become more aware and knowledgeable regarding the management and treatment of irritable bowel syndrome in the present times and thus, rapid rise in inclination and demand of IBS treatment products that improve therapeutic results across the global markets are other essential factors that is positively fueling the growth of the global irritable bowel syndrome treatment market.

However, shortage of specialized treatment that nurses all the signs of the IBS diseases and disorders as well as tough competition among the leading players of the market associated with pricing is likely to impede the market growth in the coming years.

Irritable Bowel Syndrome Treatment Market Segmentation

The global irritable bowel syndrome treatment market is segmented on the basis of drug type, medical condition, distribution channel, and region.

By Drug Type

Lubiprostone

Linaclotide

Eluxadoline

Rifaximin

Alosetron

Others

By Medical Condition

IBS-Constipation

IBS-Diarrhea

By Distribution Channel

Hospital Pharmacies

Online Pharmacies

Retail Pharmacies

By Region

North America

Latin America

Europe

Africa

Middle East

Asia Pacific

Irritable Bowel Syndrome Treatment Market Key Players

The key participating players of the global Irritable Bowel Syndrome Treatment market include Abbott Laboratories, Synergy Pharmaceuticals, Inc., Sucampo Pharmaceuticals, Inc., Valeant Pharmaceuticals International, Inc., Ardelyx, Inc., Astellas Pharma Inc., Novartis AG, GlaxoSmithKline plc, and Ironwood Pharmaceuticals, Inc., among others.

MMC Overview on Irritable Bowel Syndrome Treatment Market Report

The non-identical approach of Meridian Market Consultants stands with conceptual methods backed up with the data analysis. The novel market understanding approach makes up the standard of the assessment results that give a better opportunity for the customers to put their effort.

A research report on the Irritable Bowel Syndrome Treatment market by Meridian Market Consultants is an in-depth and extensive study of the market based on the necessary data crunching and statistical analysis. It provides a brief view of the dynamics flowing through the market, which includes the factors that support the market and the factors that are acting as impedance for the growth of the market.

Furthermore, the report includes the various trends and opportunities in the respective market in different regions for a better understanding of readers that helps to analyze the potential of the market.

Factors that are benchmarked while estimating the market

Various factors that are benchmarked while estimating the market growth includes (but not restricted to):

New product designs and launches

Current product compliance

Reimbursement

Concerns for use of Irritable Bowel Syndrome Treatment

Advantages of Irritable Bowel Syndrome Treatment

Actions taken by the manufacturer and respective regulatory authorities also impact the market growth of the segment. These factors are understood at regional level and in major countries globally for providing regional insights of the product segment in the report. This helps our clients to make informed decisions.

A mix of top-down and bottom-up approach is followed to arrive and validate our market value estimations. For a product segment where one/two manufacturer(s) dominates the market, it’s product sales, previous growth rates and market expansion plans are considered to generate market share in the global market.

1.    Global Irritable Bowel Syndrome Treatment Market Report Overview

1.1.    Introduction

1.2.    Report Description

1.3.    Methodology

2.    Global Irritable Bowel Syndrome Treatment Market Overview

2.1.    Introduction

2.1.1.    Market Definition

2.1.2.    Market Taxonomy

2.2.    Executive Summary

2.3.    Global Irritable Bowel Syndrome Treatment Market Snapshot

2.4.    Global Irritable Bowel Syndrome Treatment Market Size And Forecast, 2020–2028

2.4.1.    Introduction

2.4.2.    Market Value Forecast And Annual Growth Rate (AGR) Comparison (2020–2028)

2.5.    Global Irritable Bowel Syndrome Treatment Market Dynamics

2.5.1.    Drivers

2.5.2.    Restraints

2.5.3.    Opportunity

2.5.4.    Trends

2.6.    Porter’s Five Forces Model

2.7.    SWOT Analysis

3.    Irritable Bowel Syndrome Treatment Assessment and Analysis

3.1.    Irritable Bowel Syndrome Treatment Impact Analysis 

3.2.    Actions to encourage use of Irritable Bowel Syndrome Treatment

3.3.    Irritable Bowel Syndrome Treatment Promotional Strategy Recommendation

3.4.    Road Map Analysis

3.5.    Potential Analysis

4.    Covid-19 Impact on Irritable Bowel Syndrome Treatment Market

4.1.    Impact Analysis of Covid-19 on the global Irritable Bowel Syndrome Treatment market

4.2.    Effect On Value Chain

4.3.    Business Impact W.R.T Revenue 

4.4.    Volatility In Price 

4.5.    Effect On The Overall Trade 

4.6.    Market Impact Analysis In 2020 (Quarter Wise)

5.    Global Irritable Bowel Syndrome Treatment Market, By Drug Type

5.1.    Introduction

5.1.1.    Annual Growth Rate Comparison, By Drug Type

5.1.2.    BPS Analysis, By Drug Type

5.2.    Market Revenue (US$Mn) and Forecast, By Drug Type

5.2.1.    Lubiprostone

5.2.2.    Linaclotide

5.2.3.    Eluxadoline

5.2.4.    Rifaximin

5.2.5.    Alosetron

5.2.6.    Others

5.3.    Global Irritable Bowel Syndrome Treatment Market Attractiveness Index, By Drug Type

6.    Global Irritable Bowel Syndrome Treatment Market, By Medical Condition

6.1.    Introduction

6.1.1.    Annual Growth Rate Comparison, By Medical Condition

6.1.2.    BPS Analysis, By Medical Condition

6.2.    Market Revenue (US$Mn) and Forecast, By Medical Condition

6.2.1.    IBS-constipation

6.2.2.    IBS-diarrhea

6.3.    Global Irritable Bowel Syndrome Treatment Market Attractiveness Index, By Medical Condition

7.    Global Irritable Bowel Syndrome Treatment Market, By Distribution Channel

7.1.    Introduction

7.1.1.    Annual Growth Rate Comparison, By Distribution Channel

7.1.2.    BPS Analysis, By Distribution Channel

7.2.    Market Revenue (US$Mn) and Forecast, By Distribution Channel

7.2.1.    Hospital Pharmacies

7.2.2.    Online Pharmacies

7.2.3.    Retail Pharmacies

7.3.    Global Irritable Bowel Syndrome Treatment Market Attractiveness Index, By Distribution Channel

8.    Global Irritable Bowel Syndrome Treatment Market, By Region

8.1.    Introduction

8.1.1.    Annual Growth Rate Comparison, By Region

8.1.2.    BPS Analysis, By Region

8.2.    Market Revenue (US$Mn) and Forecast, By Region

8.2.1.    North America

8.2.2.    Latin America

8.2.3.    Europe

8.2.4.    Asia Pacific

8.2.5.    Middle East 

8.2.6.    Africa

8.3.    Global Irritable Bowel Syndrome Treatment Market Attractiveness Index, By Region

9.    North America Irritable Bowel Syndrome Treatment Market Analysis and Forecast, 2020–2028

9.1.    Introduction

9.1.1.    Annual Growth Rate Comparison, By Country

9.1.2.    BPS Analysis, By Country

9.2.    Market Revenue (US$Mn) and Forecast, By Country

9.2.1.    U.S. Irritable Bowel Syndrome Treatment Market

9.2.2.    Canada Irritable Bowel Syndrome Treatment Market

9.3.    North America Irritable Bowel Syndrome Treatment Market, By Drug Type

9.3.1.    Lubiprostone

9.3.2.    Linaclotide

9.3.3.    Eluxadoline

9.3.4.    Rifaximin

9.3.5.    Alosetron

9.3.6.    Others

9.4.    North America Irritable Bowel Syndrome Treatment Market, By Medical Condition

9.4.1.    IBS-constipation

9.4.2.    IBS-diarrhea

9.5.    North America Irritable Bowel Syndrome Treatment Market, By Distribution Channel

9.5.1.    Hospital Pharmacies

9.5.2.    Online Pharmacies

9.5.3.    Retail Pharmacies

9.6.    North America Irritable Bowel Syndrome Treatment Market Attractiveness Index

9.6.1.    By Country

9.6.2.    By Drug Type

9.6.3.    By Medical Condition

9.6.4.    By Distribution Channel

10.    Latin America Irritable Bowel Syndrome Treatment Market Analysis and Forecast, 2020–2028

10.1.    Introduction

10.1.1.    Annual Growth Rate Comparison, By Country

10.1.2.    BPS Analysis, By Country

10.2.    Market (US$Mn) Forecast, By Country

10.2.1.    Brazil Irritable Bowel Syndrome Treatment Market

10.2.2.    Mexico Irritable Bowel Syndrome Treatment Market

10.2.3.    Rest Of Latin America Irritable Bowel Syndrome Treatment Market

10.3.    Latin America Irritable Bowel Syndrome Treatment Market, By Drug Type

10.3.1.    Lubiprostone

10.3.2.    Linaclotide

10.3.3.    Eluxadoline

10.3.4.    Rifaximin

10.3.5.    Alosetron

10.3.6.    Others

10.4.    Latin America Irritable Bowel Syndrome Treatment Market, By Medical Condition

10.4.1.    IBS-constipation

10.4.2.    IBS-diarrhea

10.5.    Latin America Irritable Bowel Syndrome Treatment Market, By Distribution Channel

10.5.1.    Hospital Pharmacies

10.5.2.    Online Pharmacies

10.5.3.    Retail Pharmacies

10.6.    Latin America Irritable Bowel Syndrome Treatment Market Attractiveness Index

10.6.1.    By Country

10.6.2.    By Drug Type

10.6.3.    By Medical Condition

10.6.4.    By Distribution Channel

11.    Europe Irritable Bowel Syndrome Treatment Market Analysis and Forecast, 2020–2028

11.1.    Introduction

11.1.1.    Annual Growth Rate Comparison, By Country

11.1.2.    BPS Analysis, By Country

11.2.    Market (US$Mn) Forecast, By Country

11.2.1.    U.K. Irritable Bowel Syndrome Treatment Market

11.2.2.    Germany Irritable Bowel Syndrome Treatment Market

11.2.3.    Italy Irritable Bowel Syndrome Treatment Market

11.2.4.    France Irritable Bowel Syndrome Treatment Market

11.2.5.    Spain Irritable Bowel Syndrome Treatment Market

11.2.6.    Russia Irritable Bowel Syndrome Treatment Market

11.2.7.    Rest Of Europe Irritable Bowel Syndrome Treatment Market

11.3.    Europe Irritable Bowel Syndrome Treatment Market, By Drug Type

11.3.1.    Lubiprostone

11.3.2.    Linaclotide

11.3.3.    Eluxadoline

11.3.4.    Rifaximin

11.3.5.    Alosetron

11.3.6.    Others

11.4.    Europe Irritable Bowel Syndrome Treatment Market, By Medical Condition

11.4.1.    IBS-constipation

11.4.2.    IBS-diarrhea

11.5.    Europe Irritable Bowel Syndrome Treatment Market, By Distribution Channel

11.5.1.    Hospital Pharmacies

11.5.2.    Online Pharmacies

11.5.3.    Retail Pharmacies

11.6.    Europe Irritable Bowel Syndrome Treatment Market Attractiveness Index

11.6.1.    By Country

11.6.2.    By Drug Type

11.6.3.    By Medical Condition

11.6.4.    By Distribution Channel

12.    Asia Pacific Irritable Bowel Syndrome Treatment Market Analysis and Forecast, 2020–2028

12.1.    Introduction

12.1.1.    Annual Growth Rate Comparison, By Country

12.1.2.    BPS Analysis, By Country

12.2.    Market (US$Mn) Forecast, By Country

12.2.1.    China Irritable Bowel Syndrome Treatment Market

12.2.2.    India Irritable Bowel Syndrome Treatment Market

12.2.3.    Japan Irritable Bowel Syndrome Treatment Market

12.2.4.    Australia and New Zealand Irritable Bowel Syndrome Treatment Market

12.2.5.    South Korea Irritable Bowel Syndrome Treatment Market

12.2.6.    Rest of Asia Pacific Irritable Bowel Syndrome Treatment Market

12.3.    Asia Pacific Irritable Bowel Syndrome Treatment Market, By Drug Type

12.3.1.    Lubiprostone

12.3.2.    Linaclotide

12.3.3.    Eluxadoline

12.3.4.    Rifaximin

12.3.5.    Alosetron

12.3.6.    Others

12.4.    Asia Pacific Irritable Bowel Syndrome Treatment Market, By Medical Condition

12.4.1.    IBS-constipation

12.4.2.    IBS-diarrhea

12.5.    Asia Pacific Irritable Bowel Syndrome Treatment Market, By Distribution Channel

12.5.1.    Hospital Pharmacies

12.5.2.    Online Pharmacies

12.5.3.    Retail Pharmacies

12.6.    Asia Pacific Irritable Bowel Syndrome Treatment Market Attractiveness Index

12.6.1.    By Country

12.6.2.    By Drug Type

12.6.3.    By Medical Condition

12.6.4.    By Distribution Channel

13.    Middle East Irritable Bowel Syndrome Treatment Market Analysis and Forecast, 2020–2028

13.1.    Introduction

13.1.1.    Annual Growth Rate Comparison, By Country

13.1.2.    BPS Analysis, By Country

13.2.    Market (US$Mn) Forecast, By Country

13.2.1.    GCC Countries Irritable Bowel Syndrome Treatment Market

13.2.2.    Israel Irritable Bowel Syndrome Treatment Market

13.2.3.    Rest Of Middle East Irritable Bowel Syndrome Treatment Market

13.3.    Middle East Irritable Bowel Syndrome Treatment Market, By Drug Type

13.3.1.    Lubiprostone

13.3.2.    Linaclotide

13.3.3.    Eluxadoline

13.3.4.    Rifaximin

13.3.5.    Alosetron

13.3.6.    Others

13.4.    Middle East Irritable Bowel Syndrome Treatment Market, By Medical Condition

13.4.1.    IBS-constipation

13.4.2.    IBS-diarrhea

13.5.    Middle East Irritable Bowel Syndrome Treatment Market, By Distribution Channel

13.5.1.    Hospital Pharmacies

13.5.2.    Online Pharmacies

13.5.3.    Retail Pharmacies

13.6.    Middle East Irritable Bowel Syndrome Treatment Market Attractiveness Index

13.6.1.    By Country

13.6.2.    By Drug Type

13.6.3.    By Medical Condition

13.6.4.    By Distribution Channel

14.    Africa Irritable Bowel Syndrome Treatment Market Analysis and Forecast, 2020–2028

14.1.    Introduction

14.1.1.    Annual Growth Rate Comparison, By Country

14.1.2.    BPS Analysis, By Country

14.2.    Market (US$Mn) Forecast, By Country

14.2.1.    South Africa Countries Irritable Bowel Syndrome Treatment Market

14.2.2.    Egypt Irritable Bowel Syndrome Treatment Market

14.2.3.    North Africa Irritable Bowel Syndrome Treatment Market

14.2.4.    Rest of Africa Irritable Bowel Syndrome Treatment Market

14.3.    Africa Irritable Bowel Syndrome Treatment Market, By Drug Type

14.3.1.    Lubiprostone

14.3.2.    Linaclotide

14.3.3.    Eluxadoline

14.3.4.    Rifaximin

14.3.5.    Alosetron

14.3.6.    Others

14.4.    Africa Irritable Bowel Syndrome Treatment Market, By Medical Condition

14.4.1.    IBS-constipation

14.4.2.    IBS-diarrhea

14.5.    Africa Irritable Bowel Syndrome Treatment Market, By Distribution Channel

14.5.1.    Hospital Pharmacies

14.5.2.    Online Pharmacies

14.5.3.    Retail Pharmacies

14.6.    Africa Irritable Bowel Syndrome Treatment Market Attractiveness Index

14.6.1.    By Country

14.6.2.    By Drug Type

14.6.3.    By Medical Condition

14.6.4.    By Distribution Channel

15.    Competitive Landscape

15.1.    Company Profiles

15.1.1.    Abbott Laboratories

15.1.1.1.    Company Overview

15.1.1.2.    Financial Overview

15.1.1.3.    Key Developments

15.1.1.4.    Strategies

15.1.1.5.    Product Analysis

15.1.2.    Synergy Pharmaceuticals, Inc.

15.1.3.    Sucampo Pharmaceuticals, Inc.

15.1.4.    Valeant Pharmaceuticals International, Inc.

15.1.5.    Ardelyx, Inc.

15.1.6.    Astellas Pharma Inc.

15.1.7.    Novartis AG

15.1.8.    GlaxoSmithKline plc.

15.1.9.    Ironwood Pharmaceuticals, Inc.

16.    Acronyms

Frequently Asked Questions

  • What is the projected market size & Compound Annual Growth Rate (CAGR) of the market?
    The irritable bowel syndrome treatment market size was valued at US$ 1.8 Bn in 2020 and is expected to expand at a compound annual growth rate (CAGR) of 8.5% from 2020 to 2028
  • What are the key factors driving the growth of market?
    The rapid surge in the geriatric population, high soar in the stress level among the population, and prevalence of gastrointestinal disorders and diseases are the key factors driving the growth of market
  • What segments are covered in market report?
    The global irritable bowel syndrome treatment market is segmented on the basis of drug type, medical condition, distribution channel, and region
  • What are the key participating players in the market?
    The key participating players of the global Irritable Bowel Syndrome Treatment market include Abbott Laboratories, Synergy Pharmaceuticals, Inc., Sucampo Pharmaceuticals, Inc., Valeant Pharmaceuticals International, Inc., Ardelyx, Inc., Astellas Pharma Inc., Novartis AG, GlaxoSmithKline plc, and Ironwood Pharmaceuticals, Inc., among others